Clinical Trials Sponsored by Cerus Corporation

Total 6503 results

Cerus Corporation

Completed

In Vivo Study to Assess the Recovery and Survival of Radiolabeled Autologous INTERCEPT Apheresis Platelet Components Suspended in 100% Plasma Stored for up to 7 Days

Healthy

United States
Cerus Corporation

Completed

A Controlled, In Vivo, Pilot Study to Assess the Recovery and Survival of Radiolabeled Autologous INTERCEPT Treated 7-Day Stored Apheresis Platelet Components in 35% Plasma and 65% InterSol and 7-Day Stored Apheresis Platelet Components in 100% Plasma

Healthy
Cerus Corporation

Active, not recruiting

Study to Evaluate the Efficacy & Safety of the INTERCEPT Blood System for RBCs in Complex Cardiac Surgery Patients (ReCePI)

Anemia

United States
Cerus Corporation

Terminated

A Prospective, Open Label, Phase 1 Safety Study of Passive Immune Therapy During Acute Ebola Virus Disease Using Transfusion of INTERCEPT Plasma Prepared From Volunteer Donors Who Have Recovered From Ebola Virus Disease

Acute Ebola Virus Disease

United States
Cerus Corporation

Completed

Study to Evaluate Efficacy and Safety of S303 Treated Red Blood Cells (RBCs)in Subjects With Thalassemia Major Requiring Chronic RBC Transfusion

Thalassemia Major

Turkey, Italy
Cerus Corporation

Terminated

A Randomized, Multi-center, Open-label, Paired Controlled, Crossover In Vivo Study

Healthy

United States
Cerus Corporation

Completed

Efficacy and Safety Study of Platelets Treated for Pathogen Inactivation and Stored for Up to Seven Days (TESSI)

Thrombocytopenia

United Kingdom
Cerus Corporation

Recruiting

INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections (RedeS)

Anemia

United States, Puerto Rico
Cerus Corporation

Completed

A Open Label, Post Marketing Surveillance Study Following Transfusion of INTERCEPT Platelet Components (PIPER)

Transfusion Related Acute Lung Injury

United States
Cerus Corporation

Completed

A Study to Assess the Recovery and Lifespan of Radiolabeled Autologous S303 Treated Red Blood Cells (S303 RBC)

Focus: Assess Post Infusion Viability of S303 RBCs

United States
Cerus Corporation

Completed

Study to Assess S303 RBCs and Evaluate Safety and Efficacy in Patients Requiring Transfusion Support of Acute Anemia

Focus:Use of S303 RBCs in Patients With Acute Anemia

Germany
Caerus Corporation

Enrolling by invitation

Study to Evaluate the OrthoCor Active System for Pain Relief

Pain

United States
Acerus Pharmaceuticals Corporation

Withdrawn

Dose Finding Study of Albuterol Sulfate in Patients With Intermittent or Persistent Mild Asthma

Asthma
Acerus Pharmaceuticals Corporation

Withdrawn

Influence of Administration Route of Testosterone on Male Fertility

Hypogonadism

Netherlands
Swiss Transfusion SRC
Cerus Corporation

Withdrawn

INTERCEPT Safety Evaluation in Anemic Patients (POINT1africa)

Anemia
Acerus Pharmaceuticals Corporation

Completed

Efficacy and Tolerability of an Intra-Nasal Testosterone Product

Hypogonadism

United States
Acerus Pharmaceuticals Corporation

Completed

Efficacy and Safety of TBS-2 Testosterone Gel in Women With Acquired Female Orgasmic Disorder

Female Orgasmic Disorder

United States, Canada, Australia
Acerus Pharmaceuticals Corporation

Completed

NASOBOL in Hypogonadal Men in Comparison to Testosterone Levels in Normal Healthy Male Volunteers

Hypogonadism

United States
Acerus Pharmaceuticals Corporation

Recruiting

A Study to Monitor Ambulatory Blood Pressure Monitoring in Hypogonadal Men Treated With Nasal Testosterone Gel

Hypogonadism

United States
Acerus Pharmaceuticals Corporation

Completed

PK Study of Testosterone Nasal Gel (TBS-2) in Healthy Premenopausal Women

Female Sexual Dysfunction

United States
Acerus Pharmaceuticals Corporation

Completed

Open-Label Study, Evaluating Patient Satisfaction and Symptom Improvement When Treating Male Hypogonadism With Natesto™ (MyT)

Hypogonadism

Canada
Acerus Pharmaceuticals Corporation

Completed

Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism

Male Hypogonadism

United States
Acerus Pharmaceuticals Corporation

Completed

Efficacy of an Intranasal Testosterone Product

Hypogonadism

United States
Swiss Transfusion SRC
Cerus Corporation

Withdrawn

INTERCEPT Safety Evaluation on Whole Blood (POINT1africa)

Safety Issues
Acerus Biopharma Inc.

Terminated

Evaluation of Testosterone Nasal Gel in Hypogonadal Boys

Hypogonadism

United Kingdom
Cerus Corporation
American National Red Cross

Completed

A Prospective, Open Label, Treatment Use Study of Patient Safety Following Transfusion of INTERCEPT Platelet Components (TRUE)

Dengue Virus | Chikungunya Virus

Puerto Rico
Merus N.V.
Incyte Corporation

Recruiting

A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies

Advanced Cancer | Solid Tumor, Adult | B-cell Lymphoma, Adult

United States, Spain, Belgium, Netherlands
Coalition for National Trauma Research
Cerus Corporation

Recruiting

Plasma Resuscitation Without Lung Injury (PROPOLIS)

Burns

United States
Centro Nazionale Sangue
Terumo BCT; Cerus Corporation

Terminated

Italian Platelet Technology Assessment Study (IPTAS)

Lymphoma | Leukemia

Italy
Weill Medical College of Cornell University
Cerus Corporation

Recruiting

Transfusion of Pathogen Reduced Cryoprecipitated Fibrinogen to Expedite Product Availability in Perioperative Bleeding

Bleeding | Hypofibrinogenemia

United States
University of Utah
Acerus Pharmaceuticals Corporation

Withdrawn

Natesto Testosterone Nasal Gel for Hypogonadal Men

Sexual Dysfunction | Erectile Dysfunction

United States
University of Miami
Acerus Pharmaceuticals Corporation

Completed

A Comparison of Side Effects in Hypogonadal Men Treated With Natesto Versus Testosterone Injections

Hypogonadism, Male

United States
Cerus Endovascular, Ltd

Terminated

Pilot Study of the Contour Neurovascular SystemTM

Intracranial Aneurysm
Cerus Endovascular, Ltd

Terminated

INCA: Intracranial Aneurysm Treatment With NeXsys (INCA)

Intracranial Aneurysm

Argentina
University of Miami
Acerus Pharmaceuticals Corporation

Completed

Natesto Effects on Testosterone, Luteinizing Hormone, Follicle Stimulating Hormone and Semen Parameters

Hypogonadism, Male

United States
Cerus Endovascular, Ltd

Completed

Coil Assisted Flow Diversion Safety and Performance Study (CAFI)

Intracranial Aneurysm

Denmark, Austria, Canada, Germany, Switzerland
Cerus Endovascular, Ltd

Withdrawn

Post Market Clinical Follow-up (PMCF)Study of the Contour Neurovascular SystemTM

Intracranial Aneurysm
Cerus Endovascular, Ltd

Completed

Contour Neurovascular System - European Pre-Market Unruptured Aneurysm (CERUS)

Intracranial Aneurysm

Denmark, Germany, Austria
Cerus Endovascular, Ltd

Recruiting

US IDE Study of the Contour NEurovasCular System™ for IntraCranial Aneurysm Repair (NECC)

Aneurysm, Intracranial

United States
Emory University
National Heart, Lung, and Blood Institute (NHLBI); Cerus Corporation

Recruiting

Red Blood Cell Survival in Sickle Cell Disease

Sickle Cell Disease

United States
University of Cincinnati
Biomedical Advanced Research and Development Authority; Cerus Corporation

Unknown

Recovery and Lifespan of Red Blood Cells From Pathogen-reduced, Stored Blood Units (BIO-CR-RBC)

Red Cell Survival in Healthy Volunteers

United States
Merus N.V.

Recruiting

A Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR and Anti-c-MET Bispecific Antibody, in Patients With Advanced NSCLC and Other Solid Tumors

Gastric Cancer | Head and Neck Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma | Non-Small Cell Lung Cancer Metastatic

United States, Spain, France, Italy, Netherlands, Belgium, Korea, Republic of, Germany, Singapore
Merus N.V.

Recruiting

A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)

NSCLC Harboring NRG1 Fusion | Solid Tumours Harboring NRG1 Fusion | Pancreatic Cancer Harboring NRG1 Fusion | NRG1 Fusion

Spain, France, Israel, Belgium, Denmark, United States, Korea, Republic of, Japan, Germany, Netherlands, Austria, Canada, Italy, Norway, Singapore, Sweden, Taiwan, United Kingdom
Merus N.V.

Completed

MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.

Breast Cancer Metastatic

United States, France, Belgium, Spain, United Kingdom, Netherlands, Portugal
Merus N.V.

Available

Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor

Renal Cell Carcinoma | Breast Cancer | Head and Neck Cancer | Colorectal Cancer | Pancreatic Cancer | Prostate Cancer | Non Small Cell Lung Cancer | Cholangiocarcinoma | Solid Tumor, Unspecified, Adult | Unknown Primary Tumors | NRG1 Fusion
Merus N.V.

Active, not recruiting

MCLA-117 in Acute Myelogenous Leukemia

Acute Myeloid Leukemia | Acute Myelogenous Leukemia

United States, Italy, Netherlands, Belgium, France
Merus N.V.

Recruiting

Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers

Metastatic Castration-resistant Prostate Cancer | NSCLC Harboring NRG1 Fusion

United States
Eucatech AG
CERES GmbH

Unknown

Prospective multicEntric NonranDomized Registry (ExPEND)

Coronary Artery Disease
Nano4Imaging GmbH
CERES GmbH

Completed

Post-market Clinical Follow-up Study With Magnetic Resonance Imaging Conditional Guide Wire (MRWIREPMCF)

Congenital Heart Defect

Germany, United Kingdom
Herrmann Apparatebau GmbH
CERES GmbH

Unknown

Evaluation of Performance and Safety of Colonic Irrigation With the Colon Hydromat as a Non-oral Bowel Preparation for Colonoscopy

Colonic Irrigation

Germany

Clinical Trials Sponsored by Cerus Corporation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Togo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations